Prevalence of Cardiovascular Disease and Rate of Major Adverse Cardiovascular Events in Severe Alpha-1 Antitrypsin Deficiency COPD
Paul Ellis,Emily Bailey,Radmila Choate,Kristen Holm,Robert Sandhaus,Alice M Turner,Michael Newnham
DOI: https://doi.org/10.2147/copd.s419846
2024-01-17
International Journal of COPD
Abstract:Paul Ellis, 1, 2 Emily Bailey, 2 Radmila Choate, 3 Kristen E Holm, 4, 5 Robert A Sandhaus, 5, 6 Alice M Turner, 1, 2 Michael Newnham 1, 2 1 Institute of Applied Health Research, University of Birmingham, Birmingham, UK; 2 University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 3 University of Kentucky College of Public Health, Lexington, KY, USA; 4 Division of Neurology and Behavioural Health, National Jewish Health, Denver, CO, USA; 5 AlphaNet, Kissimmee, FL, USA; 6 Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA Correspondence: Paul Ellis, Email Aim: Alpha-1 antitrypsin deficiency is an autosomal co-dominant condition that predisposes individuals to early-onset emphysema. As with COPD, AATD-COPD is associated with pulmonary exacerbations, which impacts on overall mortality and quality of life. Though there is evidence that COPD is associated with a higher prevalence of cardiovascular disease and major adverse cardiovascular events (MACE), it is unclear if this is true for patients with AATD-COPD. Methods: Prevalence of cardiovascular disease was determined in two separate severe AATD cohorts: AlphaNet, USA and the Birmingham AATD registry, UK. All patients had preexisting lung disease. Cardiovascular disease was defined as presence of any of the following: heart failure, ischaemic heart disease, atrial fibrillation, stroke, and myocardial infarction. A Cox proportional hazards model was used to assess the impact of prior cardiovascular disease and frequent exacerbator phenotype on risk of future MACE. Results: Out of 3493 patients with severe AATD, 14.7% had prior cardiovascular disease, including stroke (2.3%), myocardial infarction (2.2%), and heart failure (2.5%). Frequent exacerbators were more likely to have preexisting cardiovascular disease compared with those with one or no exacerbations in the preceding year (63% vs 44.8%, p = 0.001). There was increased risk of future MACE in frequent exacerbators (HR 1.85, 95% CI 1.24 to 2.75), former and current smokers (HR 1.80, 95% CI 1.07 to 3.02, p = 0.026, and HR 4.04, 95% CI 1.44 to 11.32, p = 0.008, respectively), and those with prior cardiovascular disease (HR 3.81, 95% CI 2.60 to 5.58, p < 0.001). Conclusion: In severe AATD-COPD, MACE are associated with an increased exacerbation frequency, previous cardiovascular disease, and a history of smoking. Keywords: chronic obstructive pulmonary disease, COPD, alpha-1 antitrypsin deficiency, AATD, cardiovascular disease Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-dominant disorder characterised by reduced serum levels of alpha-1 antitrypsin (AAT). 1 AAT is an important serine protease inhibitor which has a role in limiting the destructive effects of proteases. Patients with severe forms of AATD, most commonly PiZZ, have significantly reduced levels of circulating AAT. 2 Uninhibited activity of proteolytic enzymes leads to accelerated elastin degradation within alveolar tissue, resulting in early-onset pulmonary emphysema. 3 The presenting features of AATD-COPD are like that of usual COPD and as such are treated in a similar way. AATD patients with progressive disease may be offered AAT augmentation therapy to slow the rate of emphysema decline. 4 As with usual COPD, patients with AATD-COPD suffer with pulmonary exacerbations, which are longer in duration and feature higher levels of inflammation compared to usual COPD. 5 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, with over 85 million people affected by CVD in Europe alone. 6 CVD is associated with an increased prevalence in patients with COPD, independent of common cardiovascular risk factors such as smoking and sedentary lifestyle. 7 The prevalence of ischaemic heart disease in patients with COPD was 2.28 times higher compared with non-COPD individuals in one meta-analysis. 8 COPD patients with co-existing CVD often experience higher rates of morbidity, including worsening quality of life, dyspnoea, and exercise tolerance 9 in addition to a higher rate of hospital admissions. 10 The association between CVD and COPD has been summarised previously 7 and may be the result of shared risk factors (genetic, environmental exposures) or shared pathophysiological mechanisms, including increased inflammation during stable COPD and pulmonary exacerbations. The role of increased inflammation in COPD is widely cited as a potential biological mechanism to ex -Abstract Truncated-
respiratory system